Kestenberg-Messina Kaitlin M. 4
4 · ADMA BIOLOGICS, INC. · Filed Feb 11, 2026
Research Summary
AI-generated summary of this filing
ADMA COO Kaitlin Kestenberg-Messina Receives RSU Awards
What Happened Kaitlin M. Kestenberg-Messina, Chief Operating Officer and SVP, Compliance of ADMA BIOLOGICS, INC. (ADMA), was granted equity awards on February 9, 2026. The Form 4 reports (A) 91,631 restricted stock units (RSUs) and (A, derivative) 144,230 RSUs — both recorded at $0.00 per share (these are compensation awards, not purchases or sales). The awards will convert into common stock upon vesting; no cash changed hands at grant.
Key Details
- Transaction date/filed: February 9, 2026 (reported on Form 4 filed Feb 11, 2026) — filing appears timely.
- Grant details: 91,631 RSUs (new grant) and 144,230 RSUs reported as derivative awards; both show $0.00 per share (compensation grants).
- Shares owned after transaction: 194,166 shares of common stock directly owned. In addition, the filing discloses approximately 386,155 unvested RSUs across multiple grants (including the new 91,631), which vest quarterly over multi-year schedules.
- Vesting notes: The new RSUs vest quarterly on each annual anniversary over four years, subject to continued service (per footnote). Other prior RSU grants listed in the filing also vest quarterly; some prior option grants vest over four years (fully vested by Feb 9, 2030 per footnote).
- Transaction code: A = Award/Grant (derivative classification noted for one grant). No tax-withholding sale or 10b5-1 plan indicated.
Context RSU grants are routine executive compensation and do not represent open-market buying or selling. They become common shares only as they vest (subject to service conditions). For retail investors, awards signal management compensation alignment but are not a direct signal of immediate insider buying/selling behavior.
Insider Transaction Report
Form 4
Kestenberg-Messina Kaitlin M.
COO and SVP, Compliance
Transactions
- Award
Common Stock
[F1][F2][F3][F4]2026-02-09+91,631→ 580,321 total - Award
Stock Option (right to buy)
[F5]2026-02-09+144,230→ 144,230 totalExercise: $16.37Exp: 2036-02-09→ Common Stock (144,230 underlying)
Footnotes (5)
- [F1]These shares represent restricted stock units ("RSUs") that will vest quarterly on each annual anniversary of the date of grant over four years in accordance with the ADMA Biologics, Inc. 2022 Equity Compensation Plan (the "Plan"), subject to the Reporting Person's continued service as of the applicable vesting date.
- [F2]Includes, as of the transaction date (i) 91,631 unvested RSUs granted on February 9, 2026, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 77,784 unvested RSUs granted on February 19, 2025, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iii) 144,240 unvested RSUs out of 192,320 RSUs granted on April 1, 2024, that will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the Reporting Person's continued service as of the applicable vesting date;
- [F3](continued from footnote 2) (iv) 15,000 unvested RSUs out of 30,000 RSUs granted on July 24, 2023, that will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the Reporting Person's continued service as of the applicable vesting date; (v) 47,500 unvested RSUs out of 95,000 RSUs granted on March 6, 2023, that will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the Reporting Person's continued service as of the applicable vesting date; (vi) 10,000 unvested RSUs out of 40,000 RSUs granted on March 7, 2022, that will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the Reporting Person's continued service as of the applicable vesting date;
- [F4](continued from footnote 3) and (vii) 194,166 shares of common stock directly owned by the Reporting Person, which reflects prior option exercises and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes.
- [F5]The options vest over four years with 25% of the shares of common stock underlying the option vesting on the one-year anniversary of the date of grant and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on February 9, 2030 in accordance with the Plan.
Signature
/s/ Kaitlin M. Kestenberg-Messina, by Michael A. Goldstein as Attorney-in-fact|2026-02-11